IL28B polymorphisms and chronic hepatitis C

Gastroenterol Clin Biol. 2010 Nov;34(11):587-9. doi: 10.1016/j.gcb.2010.06.008.

Abstract

Human genetic factors that influence HCV treatment responses have been identified by a recent landmark discovery. A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-λ3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC. More information is now needed to understand the mechanisms that underlie this association.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Biomarkers / metabolism
  • Drug Therapy, Combination
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / genetics*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Interferons
  • Interleukins / genetics*
  • Polyethylene Glycols / therapeutic use
  • Polymorphism, Genetic*
  • Recombinant Proteins
  • Ribavirin / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Antiviral Agents
  • Biomarkers
  • interferon-lambda, human
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukins
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Interferons
  • peginterferon alfa-2b